stockrow
Friday 6 November 2026
Export TIL’s income statement to Excel — free account
Instil Bio, Inc.
- EPS
- +80.6%
- Free cash flow
- +68.6%
- Total debt
- +0.91%
Quarter to June 2026, against a year earlier
6.85
0.14
−2.00%
Follow TIL
Alert me
Instil Bio, Inc. (TIL) EV/Sales
As of 6 November 2026, Instil Bio, Inc. (TIL) trades at a EV/Sales of 447×. Over the past ten years it has ranged from −1,290× (December 2022) to 17,612× (September 2021); the current reading is higher than 40% of that period. That is above the Biotechnology industry median of 9.0× and above the Healthcare sector median of 3.6×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2020 | 1,314× | — |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Dec 2020 | 1,314× | 0.00% |
| Sep 2020 | 1,314× | 0.00% |
| Jun 2020 | 1,314× | 0.00% |
| Mar 2020 | 1,314× | — |
Against its own ten years
Low −1,290×
High 17,612×
Ten-year median
492×
Current reading's percentile
18
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| PLRX Pliant Therapeutics, Inc. compare | −15.4× |
| IBIO iBio, Inc. compare | −12.8× |
| MREO Mereo BioPharma Group plc - Sponsored ADR compare | n/m |
| APLM Apollomics Inc. compare | n/m |
| HOWL Werewolf Therapeutics, Inc. compare | 2.0× |
| IMA ImageneBio, Inc. compare | 2.7× |
| HYFT MindWalk Holdings Corp. compare | 4.1× |
| CNTB Connect Biopharma Holdings Limited Sponsored ADR compare | 4.9× |
| TIL Instil Bio, Inc. | 447× |
| Biotechnology industry median | 9.0× |
| Healthcare sector median | 3.6× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)